JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Stephan Thelitz
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thelitz, S.
Right arrow Articles by Fineman, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thelitz, S.
Right arrow Articles by Fineman, J. R.
Related Collections
Right arrow Cardiac - pharmacology

J Thorac Cardiovasc Surg 2004;127:1285-1292
© 2004 The American Association for Thoracic Surgery

Cardiopulmonary support and physiology

Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs

Stephan Thelitz, MDa, Janine M. Bekker, BSb, Boaz Ovadia, MDb, Regan B. Stuart, MDb, Michael J. Johengen, BSb, Stephen M. Black, PhDc, Jeffrey R. Fineman, MDb,d,*

a Department of Cardiothoracic Surgery, University of California, San Francisco, San Francisco, Calif, USA
b Department of Pediatrics, University of California, San Francisco, San Francisco, Calif, USA
c Department of Pediatrics, Northwestern University Medical School, Chicago, Ill, USA
d Cardiovascular Research Institute, University of California, San Francisco, San Francisco, Calif, USA

Received for publication June 21, 2003; revisions received July 17, 2003; revisions received July 22, 2003; accepted for publication July 31, 2003.

* Address for reprints: Jeffrey R. Fineman, MD, Medical Center at UC San Francisco, 505 Parnassus Ave, Box 0106, San Francisco, CA 94143-0106, USA
jfineman{at}pedcard.ucsf.edu

BACKGROUND: Inhaled nitric oxide produces potent pulmonary vasodilation by activating soluble guanylate cyclase and increasing smooth muscle cell concentrations of cyclic guanosine monophosphate. However, responses are often nonsustained, and clinically significant increases in pulmonary vascular resistance have been noted on its acute withdrawal. In vitro and in vivo data suggest that inhaled nitric oxide decreases endogenous nitric oxide synthase activity. The effects of inhaled nitric oxide on the downstream mediators of the nitric oxide/cyclic guanosine monophosphate cascade, soluble guanylate cyclase and phosphodiesterase 5, have not been investigated. We sought to determine the effects of inhaled nitric oxide on endogenous cyclic guanosine monophosphate levels, soluble guanylate cyclase, and phosphodiesterase 5 protein levels in the intact lamb.

METHODS: Eleven 1-month-old lambs were mechanically ventilated. In 7 lambs, inhaled nitric oxide (40 ppm) was administered for 24 hours and then acutely withdrawn. Intermittent lung biopsy samples were obtained for cyclic guanosine monophosphate concentrations and soluble guanylate cyclase and phosphodiesterase 5 protein levels (Western blot analysis).

RESULTS: Initiation of nitric oxide decreased left pulmonary vascular resistance by 26.2%, and withdrawal rapidly increased pulmonary vascular resistance by 77.8% (P < .05). Tissue cyclic guanosine monophosphate concentrations initially increased during nitric oxide therapy but were not maintained during the 24-hour exposure. In addition, cyclic guanosine monophosphate concentrations rapidly decreased after nitric oxide withdrawal (P < .05). The {alpha} soluble guanylate cyclase (–45.7%) and ß soluble guanylate cyclase (–48.4%) protein levels decreased during nitric oxide therapy (P < .05), whereas phosphodiesterase 5 proteins levels were unchanged.

CONCLUSIONS: These data suggest a role for decreased soluble guanylate cyclase and its resulting decrease in cyclic guanosine monophosphate concentrations in the nonsustained response to nitric oxide and the rebound pulmonary hypertension noted on its acute withdrawal. Phosphodiesterase 5 inhibitors may be a useful adjunct therapy during inhaled nitric oxide to preserve cyclic guanosine monophosphate levels and thereby preserve nitric oxide responsiveness and prevent rebound pulmonary hypertension.




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
P. Namachivayam, U. Theilen, W. W. Butt, S. M. Cooper, D. J. Penny, and L. S. Shekerdemian
Sildenafil Prevents Rebound Pulmonary Hypertension after Withdrawal of Nitric Oxide in Children
Am. J. Respir. Crit. Care Med., November 1, 2006; 174(9): 1042 - 1047.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
G. A. Ross, P. Oishi, A. Azakie, S. Fratz, R. K. Fitzgerald, M. J. Johengen, C. Harmon, K. Hendricks-Munoz, J. Xu, S. M. Black, et al.
Endothelial alterations during inhaled NO in lambs with pulmonary hypertension: implications for rebound hypertension
Am J Physiol Lung Cell Mol Physiol, January 1, 2005; 288(1): L27 - L35.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 by The American Association for Thoracic Surgery.